Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects. 1997

H J Kim, and J H Im, and S O Yang, and D H Moon, and J S Ryu, and J K Bong, and K P Nam, and J H Cheon, and M C Lee, and H K Lee
Department of Nuclear Medicine, Asan Medical Center, University of Ulsan, Seoul, Korea.

Iodine-123-N-(3-iodopropene-2-yl)-2beta-carbomethoxy-3beta-( 4-chlorophenyl) tropane (123I-IPT) is a new dopamine transporter ligand that selectively binds the dopamine reuptake sites. Transporter concentrations have been known to decrease in Parkinson's disease patients. The purpose of this study was to evaluate the usefulness of IPT as an imaging agent for measuring changes in transporter concentrations in Parkinson's disease. METHODS IPT labeled with 6.78 +/- 0.67 mCi 123I was injected intravenously as a bolus into eight normal controls (mean age 41 +/- 12 yr) and 17 Parkinson's disease patients (mean age 55 +/- 9 yr). Dynamic SPECT scans of the brain were then performed for 5 min each over 120 min on a triple-headed gamma camera equipped with medium-energy collimators. Regions of interest were drawn on the middle set of the image at the level of the basal ganglia (BG) for each subject. Time-activity curves were generated for the left BG, right BG and occipital cortex (OCC). The empirical ratios between BG-OCC and OCC, which represent specific-to-nonspecific binding ratios, were computed at various time points. The statistical parameter k3/k4 was estimated by two methods: a variation of the graphic method that derives the ratio of ligand distribution volumes (R[V]) and the area ratio method (R[A]), in which the ratio is calculated from the areas under the specific and nonspecific binding activity curves. RESULTS The mean (BG-OCC)/OCC ratio for normal controls (3.07 +/- 0.73) was significantly higher than that for Parkinson's disease patients at 115 min (1.10 +/- 0.56) (p = 2.76 x 10[-5]). The mean R(V) and R(A) for normal controls were 2.06 +/- 0.27 and 1.50 +/- 0.15, respectively. The mean R(V) and R(A) for Parkinson's disease patients were 0.78 +/- 0.31 and 0.65 +/- 0.24, respectively. Both R(V) and R(A) for normal controls were significantly higher than those for Parkinson's disease patients (p values for R(V) and R(A) were 1.91 x 10(-8) and 3.46 x 10(-10), respectively). The R(V) has linear relationships with both R(A) and (BG-OCC)/OCC ratio at 115 min. The R(V) has a higher correlation (r = 0.99) with R(A) than it does with (BG-OCC)/OCC (r = 0.93). CONCLUSIONS The R(V), R(A) and (BG-OCC)/OCC for Parkinson's disease patients were clearly separated from those of normal controls, and they may be useful outcome measures for clinical diagnosis. The simplest (BG-OCC)/OCC ratio, requiring a single late time point, could be useful in clinical situations, whereas R(V) or R(A) is preferred when the dynamic data are available. The findings suggest that 123I-IPT is a useful tracer for diagnosing Parkinson's disease and studying dopamine reuptake sites.

UI MeSH Term Description Entries
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D008297 Male Males
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D005260 Female Females

Related Publications

H J Kim, and J H Im, and S O Yang, and D H Moon, and J S Ryu, and J K Bong, and K P Nam, and J H Cheon, and M C Lee, and H K Lee
January 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
H J Kim, and J H Im, and S O Yang, and D H Moon, and J S Ryu, and J K Bong, and K P Nam, and J H Cheon, and M C Lee, and H K Lee
December 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
H J Kim, and J H Im, and S O Yang, and D H Moon, and J S Ryu, and J K Bong, and K P Nam, and J H Cheon, and M C Lee, and H K Lee
September 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
H J Kim, and J H Im, and S O Yang, and D H Moon, and J S Ryu, and J K Bong, and K P Nam, and J H Cheon, and M C Lee, and H K Lee
December 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
H J Kim, and J H Im, and S O Yang, and D H Moon, and J S Ryu, and J K Bong, and K P Nam, and J H Cheon, and M C Lee, and H K Lee
November 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
H J Kim, and J H Im, and S O Yang, and D H Moon, and J S Ryu, and J K Bong, and K P Nam, and J H Cheon, and M C Lee, and H K Lee
October 2010, Biomarkers in medicine,
H J Kim, and J H Im, and S O Yang, and D H Moon, and J S Ryu, and J K Bong, and K P Nam, and J H Cheon, and M C Lee, and H K Lee
April 1999, Neurological research,
H J Kim, and J H Im, and S O Yang, and D H Moon, and J S Ryu, and J K Bong, and K P Nam, and J H Cheon, and M C Lee, and H K Lee
November 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
H J Kim, and J H Im, and S O Yang, and D H Moon, and J S Ryu, and J K Bong, and K P Nam, and J H Cheon, and M C Lee, and H K Lee
July 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
H J Kim, and J H Im, and S O Yang, and D H Moon, and J S Ryu, and J K Bong, and K P Nam, and J H Cheon, and M C Lee, and H K Lee
September 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
Copied contents to your clipboard!